Microbot Medical Inc. is gaining market momentum with its innovative LIBERTY ® Endovascular Robotic System entering 2026.
In 2025, significant achievements included FDA clearance for LIBERTY and the Limited Market Release (LMR) with positive customer feedback.
The company is gearing up for the Full Market Release (FMR) in Q2 2026 for LIBERTY, targeting a market of 2.5 million peripheral endovascular procedures annually.
FDA Clearance Achieved
Obtained FDA clearance for the single-use, remotely operated LIBERTY system for peripheral endovascular procedures.
Expansion and Collaboration
Expanded market reach through collaborations, presentations at key conferences, and bolstering the balance sheet for commercial capabilities.
Upcoming Milestones in 2026
Plans include FMR in Q2, growing customer base, expanding market opportunities, and enhancing core capabilities.
- The successful FDA clearance and LMR highlight a strong market potential for Microbot Medical.
- Collaborations with key institutions and plans for international markets signal a strategic growth trajectory for the company.
With a successful 2025 and strategic plans for 2026, Microbot Medical is poised for further growth and market penetration with its LIBERTY technology.